Treatment Patterns and Survival Outcomes Among Androgen ...

Survival Following Primary Androgen Deprivation Therapy Among ...

Primary androgen deprivation therapy was associated with lower 10-year prostate cancer–specific survival (80.1% vs 82.6%; hazard ratio [HR], ...

Treatment Pattern and Outcomes with Systemic Therapy in Men with ...

Results: The majority of patients (54%) received only androgen deprivation therapy for mPC. In patients treated with an NHT, alternate NHT was the most common ...

224P Associations of pre-existing cardiovascular disease (CVD ...

This study aimed to identify the associations of baseline CVD with treatment patterns and survival outcomes in localized prostate cancer.

Real-World Treatment Patterns and Overall Survival of Patients with ...

Among patients diagnosed with mHSPC before mCRPC (n = 3784, 72.6%), hormonal therapy was the most used therapy in both the nmHSPC and mHSPC ...

202P Complete response rates, treatment patterns and survival ...

In patients who achieved CR, the 5-year PFS rate was 59% (95%CI:39%-74%), while in those who did not, it was 9% (95%CI:4%-17%). The 5-year OS rates were 83% (95 ...

Treatment Patterns and Outcomes Among Patients With Advanced ...

Median overall survival ranged from 14.1 to 31.8 months across the 5 most frequently used first-line treatment regimens in the ≥1 LOT cohort and ...

Androgen-Deprivation Therapy for Prostate Cancer - JAMA Network

Among patients with moderately differentiated cancers, the 15-year overall survival rate was 20.0% in high-use areas vs 20.8% in low-use areas ( ...

Clinicopathological features, treatment patterns, and survival ...

In the HR-positive/human epidermal growth receptor 2 (HER2)-negative group, endocrine therapy was significantly associated with longer PFS compared with ...

Treatment patterns and outcomes in patients with nonmetastatic ...

treatment patterns; treatment utilization. ABSTRACT. Aim: Androgen receptor pathway inhibitors (ARPIs) prolong metastasis-free survival and ...

(PDF) Fifteen-Year Survival Outcomes Following Primary Androgen ...

Among patients with moderately differentiated cancers, the 15-year overall survival was 20.0% in areas with high primary ADT use vs 20.8% in areas with low use ...

"Treatment Patterns and Overall Survival Outcomes Among Patients ...

... therapy and/or androgen deprivation therapy, is associated with a 50% reduction in overall mortality compared with observation or androgen deprivation therapy ...

Real-world treatment patterns and survival outcomes for patients ...

Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study.

Cancer Research and Treatment

(B) Proportion of robotic surgery for prostate cancer according to the region. OP, operation. The 5-year ADT-free and overall survival rates ...

Treatment Patterns and Outcomes in Patients With Metastatic ...

treatment of metastatic castration-resistant prostate cancer. (mCRPC) that showed an increase in overall survival (OS) compared with standard of care.1 Over ...

Survival outcomes and prognostic factors for first-line abiraterone ...

There was no statistically significant difference in OS observed between first-line treatment with abiraterone and enzalutamide, as evidenced by ...

177 Lu-PSMA-617 versus a change of androgen receptor pathway ...

Treatment patterns and outcomes in ... Freedland, SJ ∙ Davis, M ∙ Epstein, AJ ∙ et al. Real-world treatment patterns and overall survival among ...

Real-world overall survival with abiraterone acetate versus ... - Nature

In contrast, the median (95% CI) time to subsequent treatment was significantly shorter for the abiraterone cohort (14.5 [13.4‒15.4] months) ...

Real-world treatment patterns and medical costs of prostate cancer ...

Between 2014 and 2018, 1741 patients had outpatient radiotherapy for localized or metastatic PC and 1579 patients underwent radical prostatectomy. 3502 patients ...

Treatment Patterns Among Patients With Advanced Prostate Cancer ...

Docetaxel was the most frequently used first-line treatment (35.7%), followed by abiraterone (33.3%) and enzalutamide (13.1%). Docetaxel, ...

Treatment Patterns and Survival Outcomes of Patients With Small ...

avoid the side effects associated with the long term use of Androgen. Deprivation Therapy (ADT). A pilot study was launched in our institution to evaluate ...